Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 401341, 7 pages
http://dx.doi.org/10.1155/2015/401341
Research Article

In Vivo Evaluation of TNF-Alpha in the Lungs of Patients Affected by Sarcoidosis

1Nuclear Medicine Unit, Department of Medical-Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, Ospedale S. Andrea, “Sapienza” University of Rome, Via di Grottarossa 1035, 00189 Roma, Italy
2Pneumology Unit, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Ospedale S. Andrea, “Sapienza” University of Rome, Via di Grottarossa 1035, 00189 Roma, Italy

Received 7 June 2014; Revised 9 August 2014; Accepted 11 August 2014

Academic Editor: Andor Glaudemans

Copyright © 2015 Filippo Galli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. P. Baughman, E. E. Lower, and R. M. Du Bois, “Sarcoidosis,” The Lancet, vol. 361, no. 9363, pp. 1111–1118, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Judson, “Sarcoidosis: clinical presentation, diagnosis, and approach to treatment,” The American Journal of the Medical Sciences, vol. 335, no. 1, pp. 26–33, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. A. P. Croft, D. Situnayake, O. Khair et al., “Refractory multisystem sarcoidosis responding to infliximab therapy,” Clinical Rheumatology, vol. 31, no. 6, pp. 1013–1018, 2012. View at Publisher · View at Google Scholar
  4. J. P. Utz, A. H. Limper, S. Kalra et al., “Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis,” Chest, vol. 124, no. 1, pp. 177–185, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. J. D. Doty, J. E. Mazur, and M. A. Judson, “Treatment of sarcoidosis with infliximab,” Chest, vol. 127, no. 3, pp. 1064–1071, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Saleh, S. Ghodsian, V. Yakimova, J. Henderson, and O. P. Sharma, “Effectiveness of infliximab in treating selected patients with sarcoidosis,” Respiratory Medicine, vol. 100, no. 11, pp. 2053–2059, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Sánchez-Cano, J. L. Callejas-Rubio, R. Ruiz-Villaverde, R. Ríos-Fernández, and N. Ortego-Centeno, “Off-label uses of anti-TNF therapy in three frequent disorders: behçet's disease, sarcoidosis , and noninfectious uveitis,” Mediators of Inflammation, vol. 2013, Article ID 286857, 10 pages, 2013. View at Publisher · View at Google Scholar
  8. P. Korsten, M. Mirsaeidi, and N. J. Sweiss, “Nonsteroidal therapy of sarcoidosis,” Current Opinion in Pulmonary Medicine, vol. 19, no. 5, pp. 516–523, 2013. View at Publisher · View at Google Scholar
  9. J. Domagała-Kulawik, T. Skirecki, M. Maskey-Warzechowska, H. Grubek-Jaworska, and R. Chazan, “Bronchoalveolar lavage total cell count in interstitial lung diseases—does it matter?” Inflammation, vol. 35, no. 3, pp. 803–809, 2012. View at Google Scholar
  10. R. P. Baughman, Y. Ploysongsang, R. D. Roberts, and L. Srivastava, “Effects of sarcoid and steroids on angiotensin-converting enzyme,” American Review of Respiratory Disease, vol. 128, no. 4, pp. 631–633, 1983. View at Google Scholar · View at Scopus
  11. R. H. Winterbauer, J. Lammert, M. Selland, R. Wu, D. Corley, and S. C. Springmeyer, “Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis,” Chest, vol. 104, no. 2, pp. 352–361, 1993. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Nishiyama, Y. Yamamoto, K. Fukunaga et al., “Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis,” Journal of Nuclear Medicine, vol. 47, no. 10, pp. 1571–1576, 2006. View at Google Scholar · View at Scopus
  13. J. J. Braun, R. Kessler, A. Constantinesco, and A. Imperiale, “18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 8, pp. 1537–1543, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Milman, J. Mortensen, and C. Sloth, “Fluorodeoxyglucose PET scan in pulmonary sarcoidosis during treatment with inhaled and oral corticosteroids,” Respiration, vol. 70, no. 4, pp. 408–413, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. R. G. Keijsers, F. J. Verzijlbergen, J. M. van den Bosch et al., “18F-FDG PET as a predictor of pulmonary function in sarcoidosis,” Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 28, no. 2, pp. 123–129, 2011. View at Google Scholar · View at Scopus
  16. F. Conti, G. Malviya, F. Ceccarelli et al., “Role of scintigraphy with 99mTc-infliximab predicting the response of intraarticular in patients with refractory monoarthritis,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 8, pp. 1339–1347, 2012. View at Google Scholar
  17. R. P. Baughman and M. Iannuzzi, “Tumour necrosis factor in sarcoidosis and its potential for targeted therapy,” BioDrugs, vol. 17, no. 6, pp. 425–431, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Steffen, J. Petersen, M. Oldigs et al., “Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis,” Journal of Allergy and Clinical Immunology, vol. 91, no. 4, pp. 939–949, 1993. View at Publisher · View at Google Scholar · View at Scopus
  19. M. W. Ziegenhagen, U. K. Benner, G. Zissel, P. Zabel, M. Schlaak, and J. Müller-Quernheim, “Sarcoidosis: TNF-α release from alveolar macrophages and serum level of sIL-2R are prognostic markers,” The American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 5, pp. 1586–1592, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. M. W. Ziegenhagen, M. E. Rothe, G. Zissel, and J. Müller-Quernheim, “Exaggerated TNFα release of alveolar macrophages in corticosteroid resistant sarcoidosis,” Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 19, no. 3, pp. 185–190, 2002. View at Google Scholar · View at Scopus
  21. R. P. Baughman, S. A. Strohofer, J. Buchsbaum, and E. E. Lower, “Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis,” Journal of Laboratory and Clinical Medicine, vol. 115, no. 1, pp. 36–42, 1990. View at Google Scholar · View at Scopus
  22. R. P. Baughman and E. E. Lower, “Infliximab for refractory sarcoidosis,” Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 18, no. 1, pp. 70–74, 2001. View at Google Scholar · View at Scopus
  23. L. Mallbris, A. Ljungberg, M. A. Hedblad, P. Larsson, and M. Ståhle-Bäckdahl, “Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-α therapy,” Journal of the American Academy of Dermatology, vol. 48, no. 2, pp. 290–293, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. S. D. Roberts, D. S. Wilkes, R. A. Burgett, and K. S. Knox, “Refractory sarcoidosis responding to infliximab,” Chest, vol. 124, no. 5, pp. 2028–2031, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. R. P. Baughman, M. Drent, M. Kavuru et al., “Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement,” The American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 7, pp. 795–802, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Panselinas, J. K. Rodgers, and M. A. Judson, “Clinical outcomes in sarcoidosis after cessation of infliximab treatment,” Respirology, vol. 14, no. 4, pp. 522–528, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Malviya, F. Galli, I. Sonni, M. Pacilio, and A. Signore, “Targeting T and B lymphocytes with radiolabeled antibodies for diagnostic and therapeutic applications,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 54, no. 6, pp. 654–676, 2010. View at Google Scholar · View at Scopus
  28. A. Signore, C. Lauri, and F. Galli, “Radiolabelled probes targeting infection and inflammation for personalized medicine,” Current Pharmaceutical Design, vol. 20, no. 14, pp. 2338–2345, 2014. View at Google Scholar
  29. F. Conti, R. Priori, M. S. Chimenti et al., “Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab,” Arthritis and Rheumatism, vol. 52, no. 4, pp. 1224–1226, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Chianelli, C. D'Alessandria, F. Conti et al., “New radiopharmaceuticals for imaging rheumatoid arthritis,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 3, pp. 217–225, 2006. View at Google Scholar · View at Scopus
  31. C. D'Alessandria, G. Malviya, A. Viscido et al., “Use of a 99mTc labeled anti-TNFα monoclonal antibody in Crohn's disease: in vitro and in vivo studies,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 51, no. 4, pp. 334–342, 2007. View at Google Scholar · View at Scopus
  32. A. Alavi, C. A. Buchpiguel, and A. Loessner, “Is there a role for FDG PET imaging in the management of patients with sarcoidosis?” Journal of Nuclear Medicine, vol. 35, no. 10, pp. 1650–1652, 1994. View at Google Scholar · View at Scopus
  33. H. Zhuang and A. Alavi, “18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation,” Seminars in Nuclear Medicine, vol. 32, no. 1, pp. 47–59, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. G. El-Haddad, H. Zhuang, N. Gupta, and A. Alavi, “Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders,” Seminars in Nuclear Medicine, vol. 34, no. 4, pp. 313–329, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. L. H. Brudin, S. O. Valind, C. G. Rhodes et al., “Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography,” European Journal of Nuclear Medicine, vol. 21, no. 4, pp. 297–305, 1994. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Nishiyama, Y. Yamamoto, K. Fukunaga et al., “Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis,” Journal of Nuclear Medicine, vol. 47, no. 10, pp. 1571–1576, 2006. View at Google Scholar · View at Scopus
  37. E. Prager, M. Wehrschuetz, B. Bisail et al., “Comparison of 18F-FDG and 67Ga-citrate in sarcoidosis imaging,” NuklearMedizin, vol. 47, no. 1, pp. 18–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. A. S. Teirstein, J. Machac, O. Almeida, P. Lu, M. L. Padilla, and M. C. Iannuzzi, “Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis,” Chest, vol. 132, no. 6, pp. 1949–1953, 2007. View at Publisher · View at Google Scholar · View at Scopus